HCW Biologics Stock Soars After Beijing Trimmune Deal
HCW Biologics Inc.'s stock surged over 122% in after-hours trading on Thursday, following its first-quarter earnings report. The biopharmaceutical company reported earnings per share of $0.37, far exceeding analyst estimates. Revenue climbed to $6.5 million from $5,065 a year earlier, driven by an exclusive worldwide licensing agreement with Beijing Trimmune Biotech for HCW11-006. This deal included a nonrefundable upfront license fee and an in-kind payment of $2.5 million.